Bret Baker, PA
Medical · Odessa, TXNPI 1912909789
Payments from drug & device makers
Across 260 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$767
- Lilly USA, LLC$586
- Novo Nordisk$411
- AbbVie$361
- Pfizer$342
- Boehringer Ingelheim$244
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $767 |
| Lilly USA, LLC | 43 | $586 |
| Novo Nordisk | 29 | $411 |
| AbbVie | 16 | $361 |
| Pfizer | 20 | $342 |
| Boehringer Ingelheim | 11 | $244 |
| Sanofi-aventis U.S. LLC | 14 | $226 |
| Amgen(2 entities) | 15 | $212 |
| Amarin Pharma, Inc. | 12 | $209 |
| GSK | 11 | $174 |
| Abbott | 7 | $173 |
| Astellas Pharma US Inc | 7 | $162 |
| Johnson & Johnson | 3 | $79 |
| Exact Sciences | 4 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Merck | 4 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 1 | $32 |
| Mylan Specialty L.p. | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Corcept Therapeutics | 1 | $15 |
| International Rehabilitative Sciences, Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,461 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 112 | $80,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $58,235 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $42,134 |
| OzempicSemaglutide | 40 | $38,112 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $29,640 |
| JardianceEmpagliflozin | 29 | $24,327 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $23,385 |
| JanuviaSitagliptin Phosphate | 20 | $21,769 |
| XareltoRivaroxaban | 18 | $19,146 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $14,941 |
| RybelsusSemaglutide | 13 | $12,413 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,377 |
| PremarinEstrogens, Conjugated | 16 | $9,737 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $9,658 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $342 | $90,181128 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $174 | $75,205134 claims |
| Novo NordiskOzempic, Rybelsus | $411 | $50,52553 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $767 | $48,14674 claims |
| MerckJanumet Xr, Januvia | $54 | $45,15546 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $244 | $30,14240 claims |
| Johnson & JohnsonXarelto | $79 | $19,14618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,490 medical providers in Texas.
Other medical in Odessa
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.